Minimum data elements for research reports on CFS

Brain, Behavior, and Immunity

Volumn 26, Issue 3, 2012, Pages 401-406

  Jason, Leonard A ^a   Unger, Elizabeth R ^b   Dimitrakoff, Jordan D ^c   Fagin, Adam P ^c   Houghton, Michael ^d   Cook, Dane B ^e,f   Marshall, Gailen D ^g   Klimas, Nancy ^h   Snell, Christopher ⁱ  

^a DEPAUL UNIVERSITY   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

CFS; Minimal data elements

Indexed keywords

ALDOSTERONE; ALPHA AMYLASE SALIVA ISOENZYME; BIOLOGICAL MARKER; CORTICOTROPIN; CYTOKINE; CYTOKINE RECEPTOR; FOLLITROPIN; HYDROCORTISONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN M; INTERLEUKIN 6; LUTEINIZING HORMONE; NEUROPEPTIDE Y; PROLACTIN;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CHRONIC FATIGUE SYNDROME; COGNITION; COMORBIDITY; COPING BEHAVIOR; DEMOGRAPHY; FUNCTIONAL ASSESSMENT; GENETIC ANALYSIS; HEART RATE VARIABILITY; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SELF REPORT; SKIN TEST; STANDARD; STUDY DESIGN;

CONSENSUS; FATIGUE SYNDROME, CHRONIC; HUMANS; RESEARCH DESIGN;

EID: 84857192100     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.01.014     Document Type: Review

References (47)

1. Addona T.A., Shi X., Keshishian H., Mani D.R., Burgess M., Gillette M.A., Clauser K.R., Shen D., Lewis G.D., Farrell L.A., Fifer M.A., Sabatine M.S., Gerszten R.E., Carret S.A. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotechnol. 2011, 29(7):635-643.
2. Aslakson E., Vollmer-Conna U., White P.D. The validity of an empirical delineation of heterogeneity in chronic unexplained fatigue. Pharmacogenomics 2006, 7(3):365-373.
3. Aslakson E., Vollmer-Conna U., Reeves W.C., White P.D. Replication of an empirical approach to delineate the heterogeneity of chronic unexplained fatigue. Popul. Health Metr. 2009, 7:17.
4. Aspler A.L., Bolshin C., Vernon S.D., Broderick G. Evidence of inflammatory immune signaling in chronic fatigue syndrome: a pilot study of gene expression in peripheral blood. Behav. Brain Funct. 2008, 4:44.
5. Balady G.J., Arena R., Sietsema K., et al. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010, 122(2):191-225.
6. Bergner M., Bobbit R.A., Carter W.B., Gilson B.S. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 1981, 19:787-805.
7. Carmel L., Efroni S., White P.D., Aslakson E., Vollmer-Conna U., Rajeevan M.S. Gene expression profile of empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 2006, 7(3):375-386.
8. Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., et al. Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatments protocols. J. Chronic Fatigue Syndrome 2003, 11:7-115.
9. Carruthers, B.M., van de Sande, M.I., De Meirleir, K.L., Klimas, N.G., Broderick, G., Mitchell, T., Staines, D., Powles, P., Speight, N., Vallings, R., Bateman, L., Baumgarten-Austrheim, B., Bell, D.S., Carlo-Stella, N., Chia, J., Darragh, A., Jo, D., Lewis, D., Light, A.R., Marshall-Gradisbik, S., Mena, I., Mikovits, J.A., Miwa, K., Murovska, M., Pall, M.L., Stevens, S., 2011. Myalgic encephalomyelitis: international consensus criteria. J. Intern. Med. doi:10.1111/j.1365-2796.2011.02428.x (published online on 20 July 2011).
10. Craig C.L., Marshall A.L., Sjostrom M., Bauman A.E., Booth M.L., Ainsworth B.E., Pratt M., Ekelund U., Yngve A., Sallis J.F., Oja P. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports Exerc. 2003, 35(8):1381-1395.
11. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discovery 2003, 2:566-580.
12. Friedberg F., Jason L.A. Understanding Chronic Fatigue Syndrome: An Empirical Guide to Assessment and Treatment 1998, American Psychological Association, Washington, D.C.
13. Friedberg F., Dechene L., McKenzie M.J., Fontanetta R. Symptom patterns in long-duration chronic fatigue syndrome. J. Psychosom. Res. 2000, 48:59-68.
14. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Annals of Internal Medicine 1994, 121:953-959.
15. Gerber L.H., Furst G.P. Scoring methods and application of the activity record (ACTRE) for patients with musculoskeletal disorders. Arthritis Care Res. 1992, 5:151-156.
16. Goudsmit E., Shepherd C., Dancey C.P., Howes S. ME: chronic fatigue syndrome or a distinct clinical entity?. Health Psychol. Update 2009, 18:26-31.
17. Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. Br. Med. J. 2006, 333(7568):575-578. 10.1136/bmj.38933.585764.AE.
18. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J. Hepatol. 2009, 51(5):939-948.
19. Hyde B. Are Myalgic Encephalomyelitis and chronic fatigue syndrome synonymous?. Syndrome Sentinel 1999, 3:5-8.
20. Handbook of Chronic Fatigue Syndrome 2003, John Wiley & Sons, Inc., New York, NY. L.A. Jason, P. Fennell, R.R. Taylor (Eds.).
21. Jason, L.A., Benton, M., Johnson, A., Valentine, L., 2008. The economic impact of ME/CFS: Individual and societal level costs. Dyn. Med., 7, 6. PMCID:PMC2324078.
22. Jason L.A., Evans M., Porter N., Brown M., Brown A., Hunnell J., Anderson V., Lerch A., De Meirleir K., Friedberg F. The development of a revised Canadian myalgic encephalomyelitis chronic fatigue syndrome case definition. Am. J. Biochem. Biotechnol. 2010, 6(2):120-135. 10.3844/ajbbsp. 2010.120.135.
23. Jason, L.A., Brown, A., Clyne, E., Bartgis, L., Evans, M., Brown, M., 2011a. Contrasting case definitions for chronic fatigue syndrome, myalgic encephalomyelitis/chronic fatigue syndrome and myalgic encephalomyelitis. Eval. Health Prof. doi:10.1177/0163278711424281.
24. Jason, L.A., Brown, M., Evans, M., Anderson, V., Lerch, A., Brown, A., Hunnell, J., Porter, N., 2011b. Measuring substantial reduction in functioning in patients with chronic fatigue syndrome. Disability Rehabilitation. PMID:20617920.
25. Jason, L.A., Skendrovic, B., Furst, J., Brown, A., Weng, A., Bronikowski, C., 2011c. Data mining: comparing the empiric CFS to the Canadian ME/CFS case definition. J. Clin. Psychol. (article first published online: 5 August 2011). doi:10.1002/jclp. 20827.
26. Jason, L.A., Damrongvachiraphan, D., Hunnell, J., Bartgis, L., Brown, A., Evans, M., Brown, M., 2012. Myalgic encephalomyelitis case definitions. Auton. Control Physiol. State Funct., 1, 1-14. (accessed 18.12.11). http://www.ashdin.com/journals/ACPSF/K110601.pdf.
27. Kerr J.R., Petty R., Burke B., Gough J., Fear D., Sinclair L.I., Mattey D.L., Richards S.C., Montgomery J., Baldwin D.A., Kellam P., Harrison T.J., Griffin G.E., Main J., Enlander D., Nutt D.J., Holgate S.T. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J. Infect. Dis. 2008, 197(8):1171-1184.
28. Klimas N.G., Koneru A.O. Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr. Rheumatol. Rep. 2007, 9(6):482-487.
29. Komaroff, A.L., 2000. The physical basis of CFS. The CFIDS Res. Rev., 1(2), 1-3, 11.
30. Landmark-Hsh{cyrillic}yvik H., Reinertsen K.V., Loge J.H., Kristensen V.N., Dumeaux V., Dossye{cyrillic} S., Bsh{cyrillic}rresen-Dale A.L., Edvardsen H. The genetics and epigenetics of fatigue. Phys. Med. Rehabilitation 2010, 2(5):456-465.
31. Light A.R., White A.T., Hughen R.W., Light K.C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J. Pain 2009, 10(10):1099-1112. 10.1016/j.pain.2009.06.003.
32. Lin J.S., Resch S.C., Brimmer D.J., Johnson A., Kennedy S., Burstein N., Simon C.J. The economic impact of chronic fatigue syndrome in Georgia: direct and indirect costs. Cost Effective. Resour. Allocation 2011, 9:1. 10.1186/1478-7547-9-1.
33. McEwen B.S., Stellar E. Stress and the individual. Mechanisms leading to disease. Arch. Intern. Med. 1993, 153(18):2093-2101.
34. Milani R.V., Lavie C.J., Mehra M.R., Ventura H.O. Understanding the basics of cardiopulmonary exercise testing. Mayo Clinic Proc. 2006, 81(12):1603-1611.
35. NIH's, 2011. State of the Knowledge of CFS Meeting. http://orwh.od.nih.gov/CSF%202011/SoK%20Workshop%20Report%20508%20compliant%20-%208-5-11.pdf.
36. Ramsay M.A. Myalgic Encephalomyelitis and Postviral Fatigue States: The Saga of Royal Free Disease 1988, Gower Publishing Co., London. second ed.
37. Reeves W.C., Lloyd A., Vernon S.D., Klimas N., Jason L.A. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for-resolution. BMC Health Services Res. 2003, 3:25. 10.1186/1472-6963-3-25.
38. Reeves, W.C., Wagner, D., Nisenbaum, R., Jones, J.F., Gurbaxani, B., Solomon, L., et al., 2005. Chronic fatigue syndrome - a clinically empirical approach to its definition and study. BMC Med., 3, 19. http://www.biomedcentral.com/content/pdf/1741-7015-3-19.pdf.
39. Ribeiro R.P., Roschel H., Artioli G.G., Dassouki T., Perandini L.A., Calich A.L., Pinto A.L., Lima F.R., Bonfa E., Gualano B. Cardiac autonomic impairment and chronotropic incompetence in fibromyalgia. Arthritis Res. Ther. 2011, 13(6):R190. (Epub. ahead of print).
40. Rodriguez M.A., Afari N., Buchwald D.S. National Institute of Diabetes and Digestive and Kidney Diseases Working Group on urological chronic pelvic pain. Evidence for overlap between urological and non-urological unexplained clinical conditions. J. Urol. 2009, 182:2123-2131.
41. Schulz, K.F., Altman, D.G., Moher, D., for the CONSORT Group, 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 7(3), e1000251. doi:10.1371/journal.pmed.1000251.
42. Schutzer S.S., Angel T.E., Liu T., et al. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLoS ONE 2011, 6(2):e17287.
43. Taylor C.F., Field D., Sansone S., Aerts J., Apweiler R., Ashburner M., et al. Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat. Biotechnol. 2008, 26. 1087-0156.
44. Vanness J.M., Snell C.R., Strayer D.R., Dempsey Lt., Stevens S.R. Subclassifying chronic fatigue syndrome through exercise testing. Med. Sci. Sports Exerc. 2003, 35(6):908-913.
45. Vollmer-Conna U., Aslakson E., White P.D. An empirical delineation of the heterogeneity of chronic unexplained fatigue in women. Pharmacogenomics 2006, 7(3):355-364.
46. Wagner, D., Nisenbaum, R., Heim, C., Jones, J.F., Unger, E.R., Reeves, W.C., 2005. Psychometric properties of the CDC symptom inventory for assessment of chronic fatigue syndrome. Popul. Health Metric., 3, 8. http://www.pophealthmetrics.com/content/3/1/8.
47. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30:473-483.